Clemens B. Caspar

Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry.

Background The aim was to evaluate quality of life (QoL), pain, and fatigue in patients with metastatic castration‐resistant prostate cancer (mCRPC) treated with different regimens after first‐line docetaxel, as well as disease progression. Patients and Methods Patients with mCRPC having received first‐line chemotherapy with docetaxel were eligible. Second‐line treatment choice was at the discretion of the local investigator. All patients had regular assessments of QoL with the Functional Assessment of Cancer Therapy‐Prostate (FACT‐P) questionnaire, of fatigue with the Brief Fatigue Inventory, and of pain with the McGill Pain Questionnaire‐Short Form. The primary end point was QoL maintenance defined as having a maximum decrease in 2 functional domains of the FACT‐P. Results One hundred thirty‐eight patients were included in 36 oncology centers across Switzerland. QoL analysis was available for all patients (59 who received cabazitaxel; 79 who received other therapy [OT] including 75 who received abiraterone). No significant differences for any of the end points were found between groups. A numerically higher number of patients had QoL maintenance with OT (25 of 79 patients, 32%) compared with cabazitaxel (8 of 59 patients, 14%). QoL improvement was found in 20% of patients (12 of 59) who received cabazitaxel and 24% (19 of 79) who received OT. Mean FACT‐P score did not change in a clinically relevant manner over time in either group. Pain was present in 70% of patients (96 of 138), and a pain response to treatment was noted in 22% (13 of 59) who received cabazitaxel and 29% (23 of 79) who received OT. A similar but minor improvement of fatigue was noted in both groups. Conclusion Some degree of QoL decrease was seen in most patients regardless of second‐line treatment. No significant differences in QoL parameters between cabazitaxel or other second line treatments were found. Micro‐Abstract The aim of the quality of life in second line mCRPC treatment (SEQOND) study was to prospectively evaluate quality of life (QoL) in patients with metastatic castration‐resistant prostate cancer in the second‐line setting, where different treatment options do exist. In this nationwide QoL analysis we could show an improvement of QoL in approximately 20% of patients irrespective of second‐line regimen chosen by the local investigator. No significant differences in QoL parameters between cabazitaxel or other second‐line treatments were found.